Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$75.57 USD

75.57
8,825,251

+0.57 (0.76%)

Updated May 31, 2024 03:59 PM ET

After-Market: $75.97 +0.40 (0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business

by Zacks Equity Research

Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.

Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm

by Zacks Equity Research

Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.

Boston Scientific (BSX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $36.48, marking a +0.75% move from the previous day.

Boston Scientific (BSX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $38.60, marking a +0.42% move from the previous day.

HRC vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRC vs. BSX: Which Stock Is the Better Value Option?

Q3 Earnings Mixed

by Zacks Equity Research

Q3 Earnings Mixed

Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues

by Zacks Equity Research

Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.

Boston Scientific (BSX) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.94% and -0.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Medical Products Q3 Earnings on Oct 24: BSX, ALGN & More

by Zacks Equity Research

Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.

Should You Buy Boston Scientific (BSX) Ahead of Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Tracey Ryniec headshot

The Most Spectacular Earnings Charts This Week

by Tracey Ryniec

Investors aren't spooked in these stocks. They have great earnings track records and shares are trading near their highs.

BAX vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BAX vs. BSX: Which Stock Is the Better Value Option?

Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?

by Zacks Equity Research

We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.

Boston Scientific (BSX) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Boston Scientific Stock Now

by Zacks Equity Research

Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.

Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Boston Scientific Grows on Acquisitions, Product Launches

    by Zacks Equity Research

    Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.

      Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare

      by Zacks Equity Research

      Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.

        Boston Scientific Thrives in Urology on New LithoVue Empower

        by Zacks Equity Research

        Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.

          Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite

          by Zacks Equity Research

          Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.

            Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout

            by Zacks Equity Research

            Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.

              New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

              by Zacks Equity Research

              Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

                Boston Scientific (BSX) Up 0.1% Since Last Earnings Report: Can It Continue?

                by Zacks Equity Research

                Boston Scientific (BSX) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

                  Boston Scientific to Expand Within PI Via VENITI Buyout

                  by Zacks Equity Research

                  Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.

                    Medical Product Stock Earnings on Aug 6: CAH, HSIC & More

                    by Zacks Equity Research

                    The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.